3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
12
Meningioma
4
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Neuroblastoma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Gastro-enteropancreatic neuroendocrine tumor
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Disease Progression
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma
1
Carcinoid Tumor
1
Breast Neoplasms
1
Advanced Lung Neuroendocrine Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Cyclophosphamide
13
Temozolomide
10
Magnetic Resonance Spectroscopy
10
dinutuximab
8
X-Rays
8
Specimen Handling
8
Irinotecan
8
Biopsy
8
Phantoms, Imaging
7
Topotecan
6
Nuclear Medicine Department, Hospital
6
fludarabine
5
Vincristine
5
3-Iodobenzylguanidine
5
fludarabine phosphate
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Etoposide
4
tipifarnib
3
sargramostim
3
Radiotherapy
3
Melphalan
3
Isotretinoin
3
Filgrastim
3
Doxorubicin
3
Carboplatin
3
ulixertinib
2
tazemetostat
2
selpercatinib
2
saponin QA-21V1
2
pembrolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neuroblastoma
×
lutetium Lu 177 dotatate
×
90 days
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled
NCT03966651
2026-04-29
NEUROBLU 02
Institut Claudius Regaud
Phase 1
Completed
1 enrolled